119 related articles for article (PubMed ID: 35855392)
1. A roadmap for designing narrow-spectrum antibiotics targeting bacterial pathogens.
Cao X; Landick R; Campbell EA
Microb Cell; 2022 Jul; 9(7):136-138. PubMed ID: 35855392
[No Abstract] [Full Text] [Related]
2. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile.
Cao X; Boyaci H; Chen J; Bao Y; Landick R; Campbell EA
Nature; 2022 Apr; 604(7906):541-545. PubMed ID: 35388215
[TBL] [Abstract][Full Text] [Related]
3.
Dureja C; Rutherford JT; Pavel FBA; Norseeda K; Prah I; Sun D; Hevener KE; Hurdle JG
bioRxiv; 2023 Sep; ():. PubMed ID: 37790427
[No Abstract] [Full Text] [Related]
4. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
Okumura H; Fukushima A; Taieb V; Shoji S; English M
J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029
[TBL] [Abstract][Full Text] [Related]
5. Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.
Babakhani F; Seddon J; Sears P
Antimicrob Agents Chemother; 2014 May; 58(5):2934-7. PubMed ID: 24550338
[TBL] [Abstract][Full Text] [Related]
6. Phenolic Substitution in Fidaxomicin: A Semisynthetic Approach to Antibiotic Activity Across Species.
Jung E; Kraimps A; Dittmann S; Griesser T; Costafrolaz J; Mattenberger Y; Jurt S; Viollier PH; Sander P; Sievers S; Gademann K
Chembiochem; 2023 Dec; 24(24):e202300570. PubMed ID: 37728121
[TBL] [Abstract][Full Text] [Related]
7. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.
Tashiro S; Mihara T; Sasaki M; Shimamura C; Shimamura R; Suzuki S; Yoshikawa M; Hasegawa T; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
J Infect Chemother; 2022 Nov; 28(11):1536-1545. PubMed ID: 35964806
[TBL] [Abstract][Full Text] [Related]
8. Fidaxomicin jams
Boyaci H; Chen J; Lilic M; Palka M; Mooney RA; Landick R; Darst SA; Campbell EA
Elife; 2018 Feb; 7():. PubMed ID: 29480804
[TBL] [Abstract][Full Text] [Related]
9. Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
[TBL] [Abstract][Full Text] [Related]
10. Fidaxomicin for the treatment of
Skinner AM; Scardina T; Kociolek LK
Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
[TBL] [Abstract][Full Text] [Related]
11. [Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir
Takeda S; Miki T
Nihon Yakurigaku Zasshi; 2019; 154(4):217-229. PubMed ID: 31597902
[TBL] [Abstract][Full Text] [Related]
12. Active and Secretory IgA-Coated Bacterial Fractions Elucidate Dysbiosis in Clostridium difficile Infection.
Džunková M; Moya A; Vázquez-Castellanos JF; Artacho A; Chen X; Kelly C; D'Auria G
mSphere; 2016; 1(3):. PubMed ID: 27303742
[TBL] [Abstract][Full Text] [Related]
13. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
[TBL] [Abstract][Full Text] [Related]
14. Novel fidaxomicin antibiotics through site-selective catalysis.
Dailler D; Dorst A; Schäfle D; Sander P; Gademann K
Commun Chem; 2021 May; 4(1):59. PubMed ID: 36697765
[TBL] [Abstract][Full Text] [Related]
15. The microbial diversity following antibiotic treatment of Clostridioides difficile infection.
Binyamin D; Nitzan O; Azrad M; Hamo Z; Koren O; Peretz A
BMC Gastroenterol; 2021 Apr; 21(1):166. PubMed ID: 33849457
[TBL] [Abstract][Full Text] [Related]
16. Fidaxomicin Use in the Pediatric Population with
Oliver MB; Vaughn BP
Clin Pharmacol; 2022; 14():91-98. PubMed ID: 36177387
[No Abstract] [Full Text] [Related]
17. A prospective, observational study of fidaxomicin use for
Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
[TBL] [Abstract][Full Text] [Related]
18. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic.
Sears P; Ichikawa Y; Ruiz N; Gorbach S
Ann N Y Acad Sci; 2013 Jul; 1291():33-41. PubMed ID: 23672600
[TBL] [Abstract][Full Text] [Related]
19. Gut associated metabolites and their roles in
Aguirre AM; Sorg JA
Gut Microbes; 2022; 14(1):2094672. PubMed ID: 35793402
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of transcription inhibition by the DNA mimic protein Ocr of bacteriophage T7.
Ye F; Kotta-Loizou I; Jovanovic M; Liu X; Dryden DT; Buck M; Zhang X
Elife; 2020 Feb; 9():. PubMed ID: 32039758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
